Tenax Therapeutics, Inc. (TENX)

Compare

6.30

-0.04

(-0.63%)

At close: 4:00:00 PM EDT

6.30

0.00

(0.00%)

After hours: 4:05:11 PM EDT

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano,

GlobeNewswire 2 days ago

TENX
-0.63%
Tenax Therapeutics: Q4 Earnings Snapshot

On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of 18 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 52 cents per share.

Associated Press Finance 8 days ago

TENX
-0.63%
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeuti

GlobeNewswire 8 days ago

TENX
-0.63%
Tenax Therapeutics Announces $25 Million Private Placement

CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting pl

GlobeNewswire 28 days ago

TENX
-0.63%
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with First Patient Expected to be Enrolled this Year CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopul

GlobeNewswire 28 days ago

TENX
-0.63%
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12,

GlobeNewswire 30 days ago

TENX
-0.63%
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New

GlobeNewswire last month

TENX
-0.63%
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company’s expanding Clinical Operations function i

GlobeNewswire 2 months ago

TENX
-0.63%
Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 3 months ago

TENX
-0.63%
Tenax Therapeutics: Q3 Earnings Snapshot

CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Wednesday reported a loss of $4 million in its third quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of 19 cents.

Associated Press Finance 4 months ago

TENX
-0.63%
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated Cash Runway Through End of 2027 CHAPEL HILL, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonar

GlobeNewswire 4 months ago

TENX
-0.63%
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the compa

GlobeNewswire 4 months ago

TENX
-0.63%
TENX: $100 Million Capital Raise

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported second quarter 2024 results on August 13th, 2024 in a press release and through the filing of its Form 10-Q with the SEC. The big news for Tenax has been the impressive capital raise of $100 million in August 2024. Tenax’ $100 million private placement closed one day before

Zacks Small Cap Research 7 months ago

TENX
-0.63%
Tenax Therapeutics: Q2 Earnings Snapshot

CHAPEL HILL, N.C. (AP) — Tenax Therapeutics Inc. TENX) on Tuesday reported a loss of $3.6 million in its second quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of $1.83.

Associated Press Finance 7 months ago

TENX
-0.63%
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 39 Investigative Sites Initiated In April, Hosted the KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease CHAPEL HILL, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (“Tenax”) (Nasdaq: TENX)

GlobeNewswire 7 months ago

TENX
-0.63%
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

• Funding supports advancement of oral levosimendan (TNX-103) Phase 3 development program, including completion of the ongoing LEVEL Study for the treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • Proceeds also will fund the initiation of a second Phase 3 study planned for 2025, shortening timeline to NDA submission; the protocol for this study will be submitted to FDA for comment CHAPEL HILL, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Tenax Ther

GlobeNewswire 7 months ago

TENX
-0.63%
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proc

GlobeNewswire 7 months ago

TENX
-0.63%
TENX: First Quarter Results

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. (NASDAQ:TENX) reported first quarter 2024 results on May 14th, 2024 in a press release and the filing of its Form 10-Q with the SEC. Since the beginning of the year, the company has enrolled the first patient in the oral levosimendan (TNX-103) LEVEL trial and presented data at a cardiovascular

Zacks Small Cap Research 10 months ago

TENX
-0.63%
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent Recently Hosted KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease Raised Approximately $8 Million of Net Proceeds in R

GlobeNewswire 10 months ago

TENX
-0.63%
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040Expressly provides IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF Expressly provides IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-

GlobeNewswire 10 months ago

TENX
-0.63%

Performance Overview

Return	TENX	S&P 500 (^GSPC)
YTD	+1.78%	-3.58%
1-Year	+62.79%	+8.94%
3-Year	-99.49%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Tenax Therapeutics: Q4 Earnings Snapshot

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Tenax Therapeutics Announces $25 Million Private Placement

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?

Tenax Therapeutics: Q3 Earnings Snapshot

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

TENX: $100 Million Capital Raise

Tenax Therapeutics: Q2 Earnings Snapshot

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

TENX: First Quarter Results

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Performance Overview